NCT03593954View on ClinicalTrials.gov

A Study to Assess the Effect of Ritonavir on the Single-Dose Pharmacokinetics of JNJ-61393215 in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

July 31, 2018

Primary Completion Date

September 19, 2018

Study Completion Date

September 19, 2018

Conditions
Healthy
Interventions
DRUG

JNJ-61393215

Participants will receive 2 oral administrations of 2 mg JNJ-61393215 as oral suspension.

DRUG

Ritonavir

Participants will receive 100 mg of ritonavir tablet orally.

Trial Locations (1)

84124

PRA International, Salt Lake City

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY

NCT03593954 - A Study to Assess the Effect of Ritonavir on the Single-Dose Pharmacokinetics of JNJ-61393215 in Healthy Participants | Biotech Hunter | Biotech Hunter